Cargando…

Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer

Past studies have demonstrated that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors can significantly improve clinical outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and sensitive EGFR gene mutations. Gefitinib (Iressa(®)), the first or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Ying, Li, Xiao-Fen, Chen, Jia-Qi, Dong, Cai-Xia, Weng, Shan-Shan, Huang, Jian-Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045263/ https://www.ncbi.nlm.nih.gov/pubmed/24920926 http://dx.doi.org/10.2147/OTT.S34124

Ejemplares similares

Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer
por: Sheng, Jin, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
por: Zhang, Longfeng, et al.
Publicado: (2021)

Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis
por: Zeng, Xiaohui, et al.
Publicado: (2014)

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
por: Sathyanarayanan, Vishwanath, et al.
Publicado: (2014)

Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
por: SONG, ZHENGBO, et al.
Publicado: (2013)

Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non‑small‑cell lung cancer: A meta analysis
por: Yi, Min, et al.
Publicado: (2023)

Management of patients with advanced non-small cell lung cancer: role of gefitinib
por: Velcheti, Vamsidhar, et al.
Publicado: (2010)

Gefitinib in Non Small Cell Lung Cancer
por: Costanzo, Raffaele, et al.
Publicado: (2011)

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
por: Bukowski, Ronald M
Publicado: (2011)

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
por: Yokouchi, Hiroshi, et al.
Publicado: (2007)

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer
por: Creelan, Benjamin C., et al.
Publicado: (2020)

Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
por: Gridelli, C, et al.
Publicado: (2003)

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
por: Yin, Yong-Mei, et al.
Publicado: (2010)

New treatment options for ALK+ advanced non-small-cell lung cancer: critical appraisal of ceritinib
por: Rothschild, Sacha I
Publicado: (2016)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

The Effects and Mechanisms by which Saikosaponin-D Enhances the Sensitivity of Human Non-small Cell Lung Cancer Cells to Gefitinib
por: Tang, Jian-cai, et al.
Publicado: (2019)

Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment
por: Xue, Cong, et al.
Publicado: (2015)

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer
por: Pan, Chi, et al.
Publicado: (2016)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib
por: Onn, A, et al.
Publicado: (2004)

Invasive pulmonary aspergillosis in a patient with metastatic non-small cell lung cancer after treatment with gefitinib
por: Park, Sejeong, et al.
Publicado: (2018)

Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer
por: Horiike, A, et al.
Publicado: (2011)

Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis
por: Zhu, Jun, et al.
Publicado: (2013)

Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2012)

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
por: Lu, Shun, et al.
Publicado: (2022)

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients
por: Cappuzzo, F, et al.
Publicado: (2005)

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
por: Cappuzzo, F, et al.
Publicado: (2004)

Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials
por: Ibrahim, Ezzeldin M.
Publicado: (2010)

Pharmacokinetic analysis of gefitinib in a patient with advanced non‐small cell lung cancer undergoing hemodialysis
por: Luo, Jinmei, et al.
Publicado: (2015)

Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)
por: Singh, Charu
Publicado: (2014)

Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules
por: Li, Xin, et al.
Publicado: (2014)

Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations
por: Jiang, Xuhong, et al.
Publicado: (2020)

In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer
por: Ni, Xiao Ling, et al.
Publicado: (2017)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment
por: Wang, Liang, et al.
Publicado: (2018)

Assessment of the Role of Gefitinib With Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
por: Prajapati, Raju, et al.
Publicado: (2022)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
por: Sudo, Makoto, et al.
Publicado: (2013)

Erratum in: Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
por: Araki, Takuya, et al.
Publicado: (2013)

The Role of Gefitinib in Patients with Non-small-cell Lung Cancer in India
por: Mehta, Asmita Anilkumar, et al.
Publicado: (2013)

Choroidal Metastasis of Non-Small Cell Lung Cancer That Responded to Gefitinib
por: Shimomura, Iwao, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7p3i8e1cv9ra37knlsijvumsol